Capsule Summary Slidesets

Share

Program Content

Activities

  • Larotrectinib for TRK Fusion+ Lung Cancer
    Larotrectinib in Patients With TRK Fusion–Positive Lung Cancer
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: September 15, 2021

    Expires: September 14, 2022

  • IMpower010 Subgroup Analysis
    IMpower010 Subgroup Analysis: Outcomes by Therapy Prior to Adjuvant Atezolizumab in Patients With Resected Stage IB-IIIA NSCLC
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: September 15, 2021

    Expires: September 14, 2022

  • TROPION-PanTumor01 Update
    Phase I TROPION-PanTumor01: Updated Analysis of Datopotamab Deruxtecan, a TROP2-Directed ADC, in Pretreated Advanced NSCLC Cohort
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: September 16, 2021

    Expires: September 15, 2022

  • EMPOWER-Lung 1: LA NSCLC
    Phase III EMPOWER-Lung 1 Subgroup Analysis: First-line Cemiplimab vs Chemotherapy in Patients With Locally Advanced NSCLC With PD-L1 ≥50%
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: September 16, 2021

    Expires: September 15, 2022

  • ATLANTIS
    Phase III ATLANTIS: Lurbinectedin + Doxorubicin vs CAV or Topotecan in Relapsed SCLC
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: September 17, 2021

    Expires: September 16, 2022

  • CheckMate 9LA Brain Mets
    CheckMate 9LA Post Hoc Analysis: First-line Nivolumab + Ipilimumab + CT in Patients With Advanced NSCLC and Brain Metastases
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: September 17, 2021

    Expires: September 16, 2022

  • DZD9008 in <i>EGFR</i> ex20ins+ Adv NSCLC
    Phase I Studies of Selective EGFR/HER2 Inhibitor DZD9008 in Patients With Advanced NSCLC and EGFR Exon 20 Insertion Mutations
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: September 20, 2021

    Expires: September 19, 2022

  • ATEZO-BRAIN
    ATEZO-BRAIN: Atezolizumab + Carboplatin/Pemetrexed in Advanced Nonsquamous NSCLC With Untreated Brain Metastases
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: September 20, 2021

    Expires: September 19, 2022

  • CHRYSALIS METex14 Cohort
    Phase I CHRYSALIS: Amivantamab, an EGFR-MET Bispecific Antibody, in Advanced NSCLC with MET Exon 14 Skipping Mutations
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: September 23, 2021

    Expires: September 22, 2022

  • Mobocertinib After EGFR TKI
    Phase I/II Trial of Mobocertinib in EGFR ex20ins+ Advanced NSCLC: Analysis of Patient Cohort With Disease Control on Prior EGFR TKI Therapy
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: September 23, 2021

    Expires: September 22, 2022

  • POSEIDON: Durvalumab ± Tremelimumab + CT
    Phase III POSEIDON: First-line Durvalumab ± Tremelimumab + Chemotherapy in Metastatic NSCLC
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022
  • CAR T ± Pembro in MPM
    Phase I Results of Ongoing Trial Assessing Mesothelin-Targeted CAR T-Cell Therapy ± Pembrolizumab in Malignant Pleural Cancers
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

Provided by

ProCE Banner

Supporters

AstraZeneca

Bayer Healthcare Pharma

Daiichi Sankyo, Inc.

Janssen administered by Scientific Affairs

Janssen Pharmaceutica NV

Millennium Pharmaceuticals Inc Subsidary of Takeda

Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme